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Background. As of late, dopaminergic neurotransmission has been recognized to be involved in the generation of sleep
disturbances. Increasing evidence shows that sleep disturbances in Parkinson’s disease (PD) patients are mostly related to the
disease itself, rather than being a secondary phenomenon. Evidence contained in the literature lends support to the
hypothesis that the dopaminergic nigrostriatal pathway is closely involved in the regulation of sleep patterns. Methodology/
Principal Findings. To test this hypothesis we examined the electrophysiological activity along the sleep-wake cycle of rats
submitted to a surgically induced lesion of the SNpc by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We
demonstrated that a 50% lesion of the substantia nigra pars compacta (SNpc) suffices to produce disruptions of several
parameters in the sleep-wake pattern of rats. A robust and constant decrease in the latency to the onset of slow wave sleep
(SWS) was detected throughout the five days of recording in both light [F(22.16) = 72.46, p,0.0001] and dark [F(22.16) = 75.0,
p,0.0001] periods. Also found was a pronounced increase in the percentage of sleep efficiency during the first four days of
recording [F(21.15) = 21.48, p,0.0001], in comparison to the sham group. Additionally, the reduction in the SNpc dopaminergic
neurons provoked an ablation in the percentage of rapid eye movement sleep (REM) during three days of the sleep-wake
recording period with a strong correlation (r = 0.91; p,0.0001) between the number of dopaminergic neurons lost and the
percentage decrease of REM sleep on the first day of recording. On day 4, the percentage of REM sleep during the light and
dark periods was increased, [F(22.16) = 2.46, p,0.0007], a phenomenon consistent with REM rebound. Conclusions/
Significance. We propose that dopaminergic neurons present in the SNpc possess a fundamental function in the regulation
of sleep processes, particularly in promoting REM sleep.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder mainly
characterized by motor deficits generated by the decrease of
dopaminergic neurons within the substantia nigra pars compacta
(SNpc). PD patients endure severe sleep disturbances, such as
excessive daytime sleepiness [1], rapid eye movement sleep (REM)
behavior disorders [2], ‘‘sleep attacks’’ [3] and cessation of dream
recall [4] while L-DOPA therapy has been found to enhance vivid
dream recall [5]. Recent studies show increasing evidence that the
disturbance of sleep and wakefulness in PD is most intimately
related to the disease itself and does not exclusively represent
a secondary phenomenon [6,7]. This primary effect of PD on sleep
may be linked to the previously recognized [8], although only
recently fully appreciated, role of dopamine (DA) in modulating
sleep-wake states [7].
PD is a disease characterized by impairment of the nigrostriatal
pathway. This pathway is known to control and initiate motor
plans, from the dorsal striatum to the motor cortex and back to the
cortex via the thalamus [9]. Patients with PD who have extensive
loss of dopaminergic cells within the SNpc, and less so within the
ventral tegmental area, often have increased sleepiness, which is
made worse by the presence of dopaminergic D2 receptor agonists
[10,11]. Such involvement of DA has been described subsequent
to sleep deprivation as being directly involved in the generation of
dopaminergic D2 receptor supersensitivity [12,13,14]. Moreover,
recent findings demonstrate that partial DA depletion causes
disturbances of REM sleep without affecting motor functions [15].
Additionally, a robust increase in the electrophysiological activity
of dopaminergic neurons of the ventral tegmental area has been
identified during REM sleep [16]. Along with the influence of
dopaminergic neurotransmission on generating sleep disturbances,
the evidence further supports the hypothesis that the dopaminergic
nigrostriatal pathway, specifically, is fundamental in the regulation
of sleep patterns. To test this hypothesis we examined the
electrophysiological activity along the sleep-wake cycle of rats
submitted to a surgically induced lesion of the SNpc induced by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Bilateral
guide canullas were implanted in the rats, allowing for the
microinjection of the neurotoxin directly into the SNpc. Once
microinjected, MPTP is converted, by monoamine oxidase-B in
glial cells, to 1-methyl-4-phenylpyridinium (MPP+) [17], which is
taken up via the neuronal dopamine (DA) transporter and
accumulates in dopaminergic neurons. MPP+ then becomes
concentrated in mitochondria where it inhibits complex I reducing
ATP generation and causing increased free-radical production and
subsequent neuronal death [18]. Intranigral MPTP administration
produces a burst of dopaminergic neuronal death, and also
a specific modulation in the tyrosine hydroxylase (TH) protein
expression within the substantia nigra (SN) [19,20]. In view of
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these considerations we sought to determine the fluctuations of
TH protein expression within the SN, concomitantly to the sleep-
wake pattern, in order to examine the participation of this protein
in mediating events that regulate the sleep-wake cycle.
MATERIALS AND METHODS
Subjects
All experiments were conducted in accordance with National
Institutes of Health (USA) guidelines for the care and use of
animals and abided by an approved animal protocol from our
university’s ethical committee for animal experimentation
(#0737/06). Male wistar rats weighing 280–320 g at the
beginning of the experiments were used. Rats were housed
individually in transparent acrylic cages and maintained in
standard laboratory conditions (2262uC, 12 h light/dark cycle,
lights on 7:00 A.M.) with food and water provided ad libitum.
Maximal efforts were employed to reduce the number of animals
used in the experiments yet enough to ensure unambiguous and
reliable statistical analysis and data interpretation.
Stereotaxic surgery
Rats were distributed at random into the two groups named sham
and MPTP. Animals were anesthetized with diazepam (10 mg/kg
i.p.) and ketamine (90 mg/kg i.p.) and they were mounted in
a classical stereotaxic frame (Insight Instruments). Body temper-
ature was maintained at 37uC with a regulated electric heating pad
(Harvard Apparatus). Two bipolar electrodes with four stainless-
steel screws (Ø 0.9 mm) were placed into the skull through small
holes bored into the right lateral fronto-parietal (one pair) and in
the left medial fronto-parietal (another pair) in order to monitor
bipolar electroencephalogram (EEG). The free ends of the
electrodes were soldered to a socket that was attached to the skull
with acrylic dental cement. Two nickel-chromium flexible wires
were inserted into the neck muscles in order to record the
electromyogram (EMG). Additionally, the animals were implanted
guide cannulae bilaterally (20 mm60.6 mm) 2.0 mm above the
SNpc according to the following coordinates: anteroposterior (AP):
25.0 mm from the bregma; mediolateral (ML): 62.1 mm from
the midline; dorsoventral (DV): 27.8 mm from the skull [21]. All
the rats received penicillin (20,000 U in 0.1 ml, i.m.) and sodium
diclofenac (25 mg/ml, i.p.) after surgery. One week after surgery,
the sockets were connected via flexible recording cables and
a commutator to a polygraph and computer. After three days with
the cables and the cannulae implants, the rats progressively
habituated to the apparatus allowing the performance of the 48h
basal sleep-wake states recording.
Intranigral microinjections of MPTP
After the basal sleep-wake recording of states the animals were
manipulated and gently immobilized in order to perform the
neurotoxin microinjection. Microinjections were performed dur-
ing the early part of the light period (7:00 A.M. to 9:00 A.M). Each
infusion was performed with a 30-gauge stainless injection needle
bilaterally introduced in the guide cannulae through which 2 mL
of MPTP (100 mg/mL, Sigma, prepared in sterile saline 0.9%,)
were administered. The control of the flow of the microinjection
was made by using an electronic pump (Insight Instruments) at
a rate of 0.40 mL/min for 2.5 min, followed by 2 min with the
needle in the injection site to avoid reflux. Sham microinjections
followed the same procedure but using 2 mL of sterile saline 0.9%.
Immediately after the microinjection procedure, the rats were
placed in their home cages and the data acquisition initiated for
a period up to 5 days (for details of the experimental protocol see
Fig. 1).
Sleep-wake state identification
Electrophysiological signals were recorded on a digital polygraph
(Neurofax QP 223A Nihon Kohden) at a sampling rate of
200 Hz. Filter settings of EEG were at 35 Hz and the time
constant was 0.1 s. For the EMG the filter setting was at 70 Hz
and the time constant was 0.03 s. EEG and EMG signals were
calibrated at 50 mV pulses. In homeothermic animals, sleep was
divided into two main distinct stages: slow wave sleep (SWS) and
REM sleep. The former is characterized by high-voltage slow
oscillations in the EEG associated with weak EMG activity.
During REM sleep, activity in the forebrain is comparable to
waking levels with pronounced and sustained theta rhythm in the
hippocampus and a complete loss of muscle tone [22,23].
Recordings of epochs were displayed at 15 s intervals on a high
resolution PC monitor and visually classified as wakefulness (W),
SWS and REM sleep.
TH immunohistochemistry of the SNpc neurons
For the immunohistochemical study of neuronal dopaminergic
population within the SNpc, rats were deeply anesthetized with
ketamine and intracardially perfused with saline and 4% of the
Figure 1. Schematic representation of the experimental design. After the intranigral microinjections of saline or MPTP, the rats were distributed for
sleep-wake cycle recording (n = 8/group), midbrain TH immunohistochemical examination (n = 5) and nigral TH protein expression study (n = 5).
Histological and western blotting experiments used animals that had their brains collected along the 5 days of recording (n = 5/day/group) at the
same hour they were lesioned, according to the time-points schedule.
doi:10.1371/journal.pone.0000513.g001
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fixative solution of formaldehyde in 0.1 M phosphate buffer (pH
7.4) during the period the sleep wake states were recorded, which
amounted to five days. Brains were removed from the skulls and
were immersed for 1 week in that fixative solution at 4uC.
Subsequently, the brains were placed in 30% sucrose solution for
48h before sectioning. Series of 30 mm thick sections were cut on
a cryostat in the frontal plane and collected at 20.48 mm to
20.56 mm from the bregma [21]. Tissue sections were incubated
with primary antibody anti-TH, raised in rabbits, diluted in PBS
containing 0.3% Triton X-100 (1:500; cat #AB152 Chemicon)
and reacted overnight at 4uC. Biotin conjugated secondary
antibody incubation (1:200 cat #S-1000 Vector Laboratories),
was performed for 2 h at room temperature. After several washes
in PBS, antibody complex was localized using the ABC system
(Vectastain ABC Elite kit cat #PK6101, Vector Laboratories)
followed by 3,39-diaminobenzidine reaction with nickel enhance-
ment. The sections were then mounted onto gelatin-coated slides
and coverslipped after dehydration in ascending concentrations of
ethanol-xylene solutions.
Quantification of dopaminergic neurons
Unbiased quantification of TH-labeled neurons from the SNpc
relied on the software Freeware NIH Image, 1.63. Counts were
done on 8–10 tissue sections (one in four series), and an average
count per section was determined for each animal. The selected
areas were digitized with a digital camera DP71 (Olympus
Optical) using an Olympus microscope BX50.
Determination of TH protein expression
To determine TH expression a different set of animals underwent
the same protocol of stereotaxic surgery, cannulae implantation,
Figure 2. Dopaminergic neurons present in the SNpc are reduced by half after MPTP intranigral microinjection. A representative
immunohistochemistry labeling of TH-ir neurons is shown in animals at the end of 5-day sleep-wake cycle recordings; (a) sham group (the inset
square shows the specific region depicted in the panel below), (b) MPTP group (the inset square shows the specific region depicted in the panel
below), (c) sham group in higher magnification (d) MPTP group in higher magnification, (e) bilateral quantification of the loss of TH-ir neurons in the
SNpc, (f) the loss of TH-ir neurons in the SNpc correlated closely with the decrease of REM sleep on the first day of recording, subsequent to MPTP
microinjection. The values are expressed as mean6S.E.M. **p,0.01, ANOVA followed by the Newman–Keuls test.
doi:10.1371/journal.pone.0000513.g002
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and lesioning with MPTP microinjection. To investigate the TH
expression fluctuations, generated by MPTP among the sleep-
wake cycle, 10 rats (5 of sham group and 5 of MPTP group) were
killed daily, by decapitation, at the same time of the MPTP
microinjection. After the decapitation the brains were quickly
dissected with the isolation of the SN which was immediately
frozen in dry ice and stored at 280uC until the lysis procedure.
The lysis were performed in 1.5 mL eppendorf tubes by sonication
in the presence of an ice-cold buffer containing 50 mM Tris (pH
8.0), 250 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate
(SDS), 0.25% sodium deoxycholate, 2 mM EDTA, 1mM
dithiothreitol (DTT), 20 mM phenylmethylsulfonyl fluoride
(PMSF), and protease inhibitors (Complete tablet; Roche). After
incubation on ice for 30 min extracts were centrifuged at 12,0006
g for 40 min at 4uC, and the supernatants for protein extracts were
collected and stored at 280uC for further western blotting
analysis. The aliquot of supernatant was collected for total protein
analysis [24]. Samples containing equal amounts of total protein
(5 mg per lane) were boiled with SDS sample buffer and
electrophresed in 10% SDS-polyacrylamide gels in a Mini Protean
II Dual Slab Cell (Bio-Rad). Proteins were electrophoretically
transferred to nitrocellulose membranes by means of a Mini
transblot electrophoretic transfer cell (Bio-Rad). Each membrane
was blocked for 1 h in 10% nonfat dry milk/0.5% Tween-20 in
Tris-buffered saline. Subsequently each membrane was probed
overnight at 4uC with mouse monoclonal antibodies against TH
(1:5,000; cat #T2928 Sigma) or b-tubulin III (1:500; cat
#MAB1637 Chemicon) followed by several washes in TBST
and incubation with an adequate secondary horseradish peroxi-
dase-conjugated antibody (1:5,000; cat #30021019 GE) for
60 min, and visualized by chemiluminescence (cat #sc 2048
Santa Cruz Biotechnology). The bands were quantified by using
the software ImageJ 1.32j.
Statistical methods
Differences in number of cell counts and TH protein expression
data underwent analysis of variance (ANOVA) followed by the
Newman-Keuls test. Sleep parameters were analyzed by ANOVA
and the Tukey test was used as post hoc when indicated. Pearson
correlation coefficients were calculated for comparison of loss of
dopaminergic neurons or TH protein expression with alterations
in sleep parameters. Differences were considered significant if
p,0.05. The values were expressed as mean6S.E.M.
RESULTS
Characterization of dopaminergic neuronal loss
Representative photomicrographs of TH immunohistochemistry
in the SNpc are shown for both sham and MPTP groups (Fig. 2).
The TH-ir neurons were prominently detectable in the SNpc of
sham rats. The bodies and fibers of dopaminergic neurons showed
intense staining with evident immunopositive processes in the
sham group (Fig. 2a,c). The mean number of TH-ir neurons
within the SNpc (sham, 9,7506345 vs MPTP, 4,8736176)
indicated that MPTP inflicted an expressive dopaminergic
neuronal loss of 50% [F(10.47) = 17.25, p,0.01] restricted to the
SNpc (Fig. 2e), with no detectable damages in the ventral
tegmental area.
Effects of dopaminergic cell loss in the SNpc upon
sleep-wake cycles
The data indicated that a 50% dopaminergic neuronal loss
restricted to the SNpc, inflicted by MPTP, was able to produce
a robust and constant decrease in the latency to the onset of SWS
during the 5 days of recording in both light [F(22.16) = 72.46,
p,0.0001] and dark [F(22.16) = 75.0, p,0.0001] periods (Fig. 3a).
In addition, this nigral dopaminergic depletion also increased the
latency to REM sleep during the light [F(22.16) = 14.73, p,0.001]
and dark [F(22.16) = 14.70, p,0.0001] periods 1 day after
neurotoxin microinjection (Fig. 3b). MPTP-induced dopaminergic
neuronal loss also generated pronounced increase in the
percentage of sleep efficiency during the first 4 of the 5 days of
recording [F(21.15) = 21.48, p,0.0001] in comparison to the sham
group (Fig. 4). The percentage of SWS was increased in the MPTP
group on days 2 and 3 only in the dark period [F(21.15) = 4.54,
p,0.0001] compared to the sham group (Fig. 5). In contrast, the
reduction in the dopaminergic neuronal population, resident in
the SNpc provoked an ablation in the percentage of REM sleep
during days 1 (for light and dark periods), 2 and 3 (for the light
period only) (Fig. 6). Moreover, there was a strong correlation
between the number of TH-ir neurons lost and the percentage
decrease of REM sleep on the first day of recording after MPTP
lesion (r = 0.91; p,0.0001, Fig. 2f). On day 4, REM sleep
presented an increase in both periods [F(22.16) = 2.46, p,0.0007]
(Fig. 6). All the sleep parameters return to basal values at day 5
after the MPTP exposure, with the exception of latency to SWS.
This observation indicated the end point of the examination
paradigm.
Figure 3. Dual effects upon the latencies to SWS and REM sleep after
selective SNpc lesion. (a) Latency to SWS showed to be decreased at all
time-points after MPTP exposure, in both light and dark periods. (b)
Latency to REM sleep was increased in the light and dark periods after
MPTP only on the first day of recording. The values are expressed as
mean6S.E.M. *p,0.05, ***p,0.0001 compared to baseline, ANOVA
followed by the Tukey test.
doi:10.1371/journal.pone.0000513.g003
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Figure 4. Nigral disruption promoted an increase in the sleep efficiency during the first four days of recording. SNpc dopaminergic neuronal loss
promoted a sustained increase in the percentage of sleep efficiency on the first 3 days of the sleep-wake recording, in both light and dark periods. On
the fourth day, the increase in this parameter occurred only in the dark period. The values are expressed as mean6S.E.M. **p,0.05 compared to
baseline, #p,0.05 compared to the respective sham group, ANOVA followed by the Tukey test.
doi:10.1371/journal.pone.0000513.g004
Figure 5. Slight increase in the percentage of SWS after SNpc lesion. The percentage of SWS was increased on the second and fourth days, only in
the dark periods, indicating sleepiness effect in the activity period of the rodent. The values are expressed as mean6S.E.M. *p,0.05 compared to
those of baseline, #p,0.05 compared to the respective sham group. ANOVA followed by the Tukey test.
doi:10.1371/journal.pone.0000513.g005
Figure 6. SNpc neurons are fundamental in the generation of REM sleep. The percentage of REM sleep, of the MPTP group, was reduced on the
first three days of recording, in both light and dark periods. In contrast, the percentage of REM sleep significantly rose on the fourth day, probably as
a compensatory rebound mechanism. The values are expressed as mean6S.E.M. *p,0.05 compared to those of baseline, #p,0.05 compared to the
respective sham group, yp,0.0007 compared to the MPTP group day 1. ANOVA followed by the Tukey test.
doi:10.1371/journal.pone.0000513.g006
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Fluctuations in the nigral TH protein expression
after MPTP microinjection
A single band was observed at the expected molecular mass of
60 kDa for the groups tested at the distinct time-points examined.
Denser TH-positive bands were consistently observed in the sham
group (Fig. 7a,b). There was a significant decrease of 50.1% of TH
expression in the SN of the MPTP group in comparison to the
sham group [F(9.99) = 2.95, p,0.004] on the first day after the
neurotoxin microinjection (Fig. 7b). This dramatic decrease in TH
expression at day 1 was not seen in later time-points. Two days
after the microinjection TH expression in the MPTP group was
98% in comparison to the sham group of the respective day. A
similar situation was observed for the following time-points: 3
(p = 0.07, 86%), 4 (p = 0.06, 82%) and 5 (p= 0.11, 100%) days
after the microinjections. Weak correlations were observed
between TH protein expression and sleep parameters (sleep
efficiency r =20.64, p = 0.042; SWS r=20.30, p = 0.39; REM
r= 0.20, p = 0.57) along the time-points.
DISCUSSION
The main findings herein are that the dopaminergic neurons
located within the SNpc played an important role in regulating
sleep patterns in rats, and that disturbances in this particular
neuronal population produced severe complications in all the sleep
parameters examined, especially in REM sleep. To the extent of
our knowledge this is the first paper that provides direct evidence
of SNpc function in sleep. The impairment in REM sleep
presented a transient characteristic which culminated a few days
after the nigral disruption with a strong increase in the percentage
of REM sleep, during the light and dark periods. The present
findings dovetail with growing evidence showing the influence of
DA in the regulation of sleep-wake pattern and the significant
repercussions that eventual reductions of this neurotransmitter
may generate, particularly in PD patients.
A recent experiment has shown a coordinated bursting mode of
activity of dopaminergic neurons, located in the ventral tegmental
area, initiated 10–20 s before the onset of REM sleep and lasting
until the end of this sleep stage [16]. It has been proposed that during
the sleep-wake cycle the temporal pattern of firing rates alters in
midbrain dopaminergic cells. The available evidence tends to
indicate that during wakefulness there occurs an increase of burst
firing activity of dopaminergic neurons, and enhanced release of DA
in the nucleus accumbens, and a number of forebrain structures [25].
Hence on the basis of our findings, different features of the
dopaminergic neurons are revealed, considering that they are not
exclusively related to wakefulness as initially postulated, according
to previous lesion studies [26,27]. Nevertheless, a large range of
different cell populations are damaged with the systemic adminis-
tration of a neurotoxin or even by electrolytic protocols. In this sense,
the present study promoted a dopaminergic lesion compatible with
the extension of the area that was examined, i.e. the SNpc. We
adopted the intranigral microinjection of MPTP as a more reliable
and accurate choice to produce only specific dopaminergic neuronal
death. This protocol resorts to precise delivery of MPTP to the
SNpc, relying on its specificity to the dopaminergic transporter. The
TH immunohistochemistry examination revealed that MPTP
produced a reduction of 50% in the dopaminergic neurons in the
SNpc. In addition, neuronal morphology was apparently preserved
in the remaining neurons of the MPTP group, despite the
remarkable apoptosis inflicted by MPTP [28,29]. At this point,
a note of caution should be added: MPTP microinjection, in our
experience, can achieve a plateau of dopaminergic neuronal loss of
around 50%, without affecting adjacent areas. In this sense, our
hypothesis is limited exclusively to the influence of SNpc neurons in
the patterns of the sleep-wake cycle. To ensure an unbiased lesion
protocol, we preferred not to produce a more extensive lesion,
guaranteeing that the physiological effects occurred only as
consequence of SNpc lesion.
The electrophysiological data indicated that the absence of half
of the dopaminergic neurons within the SNpc provoked a major
impairment in the sleep-wake parameters. Some manifestations, as
indicated by the decrease in the latency to SWS, initiated almost
immediately after the neurotoxin microinjection, corroborating
a previous study with systemic administration of MPTP in cats
[30], and those alterations were continuously identified until the
end of the experimentation. In relation to these findings, it is
noteworthy to consider that the impairments of these parameters
could be characterized as an overwhelming episode of sleep,
similar to ‘‘sleep attacks’’ which is a manifestation experienced by
1–21% of PD patients [3,31]. We also demonstrated that latency
Figure 7. Western blotting analysis of the Nigral TH protein
expression along the sleep-wake cycle recording. (a) Serial dilution
of nigral TH protein was loaded across the lanes and visualized with
enhanced chemiluminescence. A standard curve was generated from
densitometric values obtained from computer analysis of digitized film
from immunoblot. A linear relationship between optical density and the
amount of protein was observed with a strong correlation. (b) TH
protein expression was significantly decreased in the MPTP group in
comparison to the sham on the first day after the microinjection. Two
days after MPTP, TH presented an expression of 98% in comparison to
the sham group, on the respective day. A similar situation was observed
for the subsequent time-points analyzed. The values are expressed as
mean6S.E.M. *p,0.05 compared to those of baseline. ANOVA followed
by the Newman-Keuls test.
doi:10.1371/journal.pone.0000513.g007
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to REM sleep presented a punctual augment on the very first day
after the nigral lesion, with a return to baseline values on the
subsequent days of recording. This finding is strengthened by the
dramatic reduction in the percentage of REM sleep observed in
the first day after MPTP, which is highly correlated to the number
of dopaminergic TH-ir neurons lost within the SNpc. Otherwise,
TH protein expression in the SN did not present significant
correlation to any recorded sleep parameter. Such evidence
indicates that sleep-wake patterns are more closely related to
function of nigral dopaminergic neurons than exclusively to
variations of TH expression.
An analogous pattern of deficit in REM sleep was observed the
following days, with some level of fluctuation in the percentage of
REM sleep although on the 4th day of recording, REM sleep
robustly increased in both light and dark periods. Such unexpected
result suggests the activation of a compensatory mechanism which
led to an irrefutable augmentation in the percentage of REM
sleep. It is not unreasonable to suggest that this phenomenon can
be considering a rebound of REM sleep.
The dopaminergic nigrostriatal lesion promoted a significant
reduction in the TH protein expression, and suggestively in DA
biosynthesis. Nevertheless, 50% of the dopaminergic nigral
neurons survived generating a potential plastic response to this
neurotoxic assault. This response is possibly mediated by the TH
protein up-regulation and also by an important post-synaptic event
defined as D2 dopaminergic supersensitivity [12,13,14], which is
unleashed mainly by reduction of DA in the synaptic cleft.
Considering the percentage of SWS we observed an increase
during the 2nd and 3rd days of recording followed by a return to
baseline values after those time-points. Notably, the reduction of
the dopaminergic nigral population generated a pronounced
potentiation of SWS to the detriment of REM sleep. In addition,
sleep efficiency was found to be augmented indicating increased
sleepiness during the four first days in the lesioned rats.
We proposed that dopaminergic neurons present in the SNpc
possess a fundamental role in the regulation of sleep processes,
particularly in promoting REM sleep. It also should be mentioned
that flanking areas of the SNpc, like the ventral tegmental area, have
recently been reported to be involved in the regulation [16], and
perhaps genesis, of REM sleep as we demonstrated for the SNpc.
Besides, clinical evidence demonstrate a transient restoration of
motor control in PD patients during REM sleep [32], representing, in
the light of our study, an intersection between these two physiological
functions, with the nigrostriatal pathway playing a key role.
In conclusion, we reported herein that dopaminergic neurons
resident in the SNpc possess a central role in the regulation of sleep
processes, particularly of REM sleep. This evidence directly
demonstrates that the SNpc is an integrative area of biological
function, well known to be responsible for voluntary motor control,
and herein described as an important center of sleep regulation.
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